This symposium will examine the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of LA SCCHN. The cisplatin-based chemoradiation that is the current standard of care for these patients offers only limited overall survival and is accompanied by early and late toxicities. As such, the emergence of antagonists of IAPs, with a unique MOA and the potential to dramatically improve treatment outcomes and the quality of life for patients with LA SCCHN, could be a game changer. Our expert faculty present clinical data that support the potential inclusion of antagonists of IAPs in the management of LA SCCHN and discuss when this treatment is likely to enter the clinic. Join us and learn why antagonists of IAPs may represent one of the most important breakthroughs over the last 30 years in the management of LA SCCHN.